您即将离开沛嘉医疗中文官网。
您刚才点击了进入另一网站的链接。如果继续,您可能会进入由第三方运行的网站。 我们不负责对非沛嘉医疗中文官网上的内容进行审核与管控,亦不会对您在非沛嘉医疗中文网上的任何商业交易或事物承担任何责任。您使用其他网站时,必须遵循该网站的使用条款及隐私声明。 其他网站上的部分产品和信息可能并未在您所在地区或国家获得批准。
取消
继续
Brief News on Innovation
Company News Brief News on Innovation
Brief News on Innovation
THE LATEST PROGRESS IN THE FIM STUDY OF MonarQ™ IN EUROPE AND AMERICA WAS ANNOUNCED AT TCT 2024
2024.11.06
THE LATEST PROGRESS IN THE FIM STUDY OF ···
Since the first implantation in November 2023, a total of 9 patients have been enrolled in MonarQ™ ···
TWO-YEAR FOLLOW-UP RESULTS OF HighLife® FEASIBILITY STUDY WERE ANNOUNCED AT TCT 2024
2024.11.05
TWO-YEAR FOLLOW-UP RESULTS OF HighLife® ···
Two-year clinical data of the HighLife® TSMVR technology's feasibility trial involving 30 cases···
SmartWave LITHOTRIPSY VALVULOPLASTY TECHNOLOGY SHOWCASED AT TCT2024
2024.11.04
SmartWave LITHOTRIPSY VALVULOPLASTY TECH···
In the trial exploring the effectiveness and safety of using the SmartWave lithotripsy valvuloplast···
THE 2-YEAR RESULTS OF ALIGN-AR TRIAL OF JENAVALVE Trilogy™ HEART VALVE SYSTEM WERE PRESENTED AT TCT2024
2024.11.01
THE 2-YEAR RESULTS OF ALIGN-AR TRIAL OF ···
At 2 years, the cardiac mortality rate was still lower than the study’s prespecified performance go···
INTERPRETATION OF PRE-MARKET CLINICAL DATA FOR YonFlow® FLOW DIVERTER
2024.10.31
INTERPRETATION OF PRE-MARKET CLINICAL DA···
During October 24-27, 2024, the pre-market clinical data for the YonFlow® flow diverter was offici···
PROFESSOR WANG YAN'S TEAM AT XIAMEN UNIVERSITY CARDIOVASCULAR HOSPITAL SUCCESSFULLY COMPLETES THE FIRST ENROLLMENT IN THE CHINESE CLINICAL TRIAL CENTER FOR PEIJIA HighLife® TSMVR SYSTEM
2024.09.27
PROFESSOR WANG YAN'S TEAM AT XIAMEN UNIV···
On September 24, 2024, led by President Wang Yan of Xiamen University Affiliated Cardiovascular Ho···
REGISTERED CLINICAL DATA OF TaurusElite® AND TaurusTrioTM DEBUT AT PCR-CCV 2024
2024.09.24
REGISTERED CLINICAL DATA OF TaurusElite®···
During September 20-22, 2024, Peijia presented multiple clinical data at the PCR-CIT China Chengdu ···
PEIJIA MEDICAL RECEIVES THE NMPA APPROVAL FOR THE REGISTRATION APPLICATION OF TaurusMax™ TAVR SYSTEM
2024.08.15
PEIJIA MEDICAL RECEIVES THE NMPA APPROVA···
Peijia Medical received the NMPA approval for the registration application of TaurusMax™ in August 1···
HighLife® Transseptal Mitral Valve Replacement (TSMVR) System: Latest Updates Presented at New York Valves 2024, FDA Approved IDE Application to Initiate US Piovtal Study for Treatment of Mitral Regurgitation
2024.06.13
HighLife® Transseptal Mitral Valve Repla···
From June 5 to 7, 2024, the New York Valves (NYV) conference was held, where Prof. Nicolo Piazza of ···
MonarQ™ Transcatheter Tricuspid Valve Replacement (TTVR) Innovative Device: The Latest Results of the FIM Clinical Implantation Were Presented at New York Valves 2024
2024.06.13
MonarQ™ Transcatheter Tricuspid Valve Re···
From June 5 to 7, 2024, the latest results of the FIM clinical implantation of MonarQTM, an innovati···
PEIJIA MEDICAL SHONE AT TWO MAJOR  STRUCTURAL HEART DISEASE  CONGRESSES TO DEMONSTRATE  INNOVATION
2024.04.22
PEIJIA MEDICAL SHONE AT TWO MAJOR STRUC···
On March 18-24 and April 15-20, 2024, Peijia Medical shone at the 5th China Structural Heart Disease···
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) SYSTEM APPROVED BY THE NMPA
2024.04.19
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S···
On April 18, 2024, new AV21 specification of TaurusOne® and TaurusElite® TAVR systems, developed by ···
Top